Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study-Reference-Cited by-同舟云学术

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Published:2010-09 Issue:9 Volume:34 Page:1143-1150
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Gattermann Norbert,Finelli Carlo,Porta Matteo Della,Fenaux Pierre,Ganser Arnold,Guerci-Bresler Agnes,Schmid Mathias,Taylor Kerry,Vassilieff Dominique,Habr Dany,Domokos Gabor,Roubert Bernard,Rose Christian

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Disorders of iron metabolism;Andrews;N Engl J Med,1999

2. Influence of RBC transfusions on clinical outcomes among USA Medicare beneficiaries with newly diagnosed myelodysplastic syndromes;Goldberg;Leuk Res,2009

3. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome;Sanz;Blood,2008

4. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci-Bresler A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010; [Epub ahead of print].

5. Consensus statement on iron overload in myelodysplastic syndromes;Bennett;Am J Hematol,2008

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelodysplastic Syndrome;Comprehensive Hematology and Stem Cell Research;2024

2. Iron and copper: critical executioners of ferroptosis, cuproptosis and other forms of cell death;Cell Communication and Signaling;2023-11-16

3. Traitement des syndromes myélodysplasiques de bas risque;Bulletin du Cancer;2023-11

4. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR;Journal of Clinical Medicine;2023-10-17

5. Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation;Transplantation and Cellular Therapy;2023-01